Stockscreener 앱 받기
5.83
2.83%
-0.17
시간 외 거래:
5.84
0.010
+0.17%
전일 마감가:
$6.00
열려 있는:
$5.98
하루 거래량:
12,418
Relative Volume:
0.15
시가총액:
$100.15M
수익:
$37.16M
순이익/손실:
$-17.83M
주가수익비율:
-5.6383
EPS:
-1.034
순현금흐름:
$-14.22M
1주 성능:
+1.39%
1개월 성능:
-7.02%
6개월 성능:
-27.58%
1년 성능:
-9.12%
1일 변동 폭
$5.83
$6.105
1주일 범위
$5.60
$6.22
52주 변동 폭
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
명칭
Verrica Pharmaceuticals Inc
전화
484-453-3300
주소
44 WEST GAY STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
5.83 | 99.81M | 37.16M | -17.83M | -14.22M | -1.034 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2023-03-22 | 개시 | Jefferies | Buy |
| 2023-02-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Outperform |
| 2020-12-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-24 | 개시 | Northland Capital | Outperform |
| 2020-03-24 | 개시 | Needham | Buy |
| 2019-02-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Verrica Pharmaceuticals Inc 주식(VRCA)의 최신 뉴스
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISI - GuruFocus
Verrica’s COVE-3 Wart Study Moves Forward, Offering a Small but Notable Catalyst for VRCA and VEEV - TipRanks
Verrica Pharmaceuticals (NASDAQ: VRCA) director awarded 16,000 stock options at $6.04 - Stock Titan
Director at Verrica (NASDAQ: VRCA) receives 16,000 stock options - Stock Titan
Verrica (VRCA) director Diem Nguyen awarded 16,000 stock options at $6.04 - Stock Titan
Verrica (VRCA) CMO receives 233,840 performance-vested stock options - Stock Titan
Verrica (VRCA) COO receives 171,340 stock options with price hurdles - Stock Titan
Verrica (VRCA) CEO awarded 512,269 options with $15 and $25 vesting hurdles - Stock Titan
Director Gavin Corcoran receives 16,000 Verrica (VRCA) stock options at $6.04 - Stock Titan
Verrica Pharmaceuticals (NASDAQ: VRCA) shareholders approve new equity plan and re-elect directors - Stock Titan
VRCA: YCANTH adoption accelerates, pipeline advances, and cash runway extends into 2027 - TradingView
Number of shareholders of Verrica Pharmaceuticals Inc. – LS:A41A98 - TradingView
Verrica Shares Drop With Jefferies Conference Ahead, Cash Warning Still in Focus - Bez Kabli
Verrica Stock Slips Before Jefferies as Cash Warning Shadows YCANTH Growth - Bez Kabli
VRCA Stock Price, Quote & Chart | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill
Verrica Pharmaceuticals to present at Jefferies Global Healthcare Conference June 4, 2026 - Pluang
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
VRCA Assumed by HC Wainwright & Co. -- Buy Rating Announced - GuruFocus
H.C. Wainwright Initiates Verrica Pharmaceuticals(VRCA.US) With Buy Rating, Announces Target Price $12 - Moomoo
Verrica Pharmaceuticals (VRCA) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Sees Modest Stock GainRevenue Per Share - Newser
Earnings Call Summary | Verrica Pharmaceuticals(VRCA.US) Q1 2026 Earnings Conference - 富途牛牛
Number of shareholders of Verrica Pharmaceuticals Inc. – LSX:A41A98 - TradingView
Verrica Pharmaceuticals (VRCA) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Stage ContinuesCrowd Risk Alerts - Newser
Verrica Expands YCANTH Sales as Wart Trials Advance - MyChesCo
Verrica Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings call transcript: Verrica Pharmaceuticals Q1 2026 shows revenue growth - Investing.com Nigeria
Verrica Pharmaceuticals Q1 earnings call highlights - MSN
Verrica Pharmaceuticals Inc. (VRCA) reports Q1 loss, tops revenue estimates - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q1 2026 Earnings Call Transcript - Insider Monkey
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call - Sahm
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Sahm
Verrica Pharmaceuticals (VRCA) Returns To Larger Q1 Loss Challenging Bullish Profitability Narratives - Sahm
Verrica targets COVE-3 initiation by mid-2026 as Q1 dispensed YCANTH units rise 12.1% sequentially - MSN
Verrica (VRCA) Q1 2026 Earnings Transcript - AOL.com
Needham Maintains Verrica Pharmaceuticals(VRCA.US) With Hold Rating - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlig - GuruFocus
Dermatology drug developer Verrica to present at Nasdaq investor event - Stock Titan
Verrica Pharmaceuticals (VRCA) Reports Strong Q1 2026 Growth for YCANTH - GuruFocus
Verrica Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Verrica Pharmaceuticals Q1 Earnings Call Highlights - inkl
Verrica Pharmaceuticals (VRCA) Reports Strong Q1 Revenue Growth - GuruFocus
VRCA: Record Q1 growth for YCANTH, pipeline progress, and global expansion drive positive outlook - TradingView
Verrica Pharmaceuticals 1Q Rev $5.02M >VRCA - Moomoo
Verrica Pharmaceuticals (VRCA) Q1 2026: EPS Not Disclosed (Est - GuruFocus
VRCA: Record YCANTH growth, robust pipeline progress, and strong cash position highlight Q1 2026 - TradingView
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
[10-Q] Verrica Pharmaceuticals Inc. Quarterly Earnings Report - Stock Titan
Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentum - ChartMill
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results - Sahm
Verrica Pharmaceuticals Inc (VRCA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Verrica Pharmaceuticals Inc 주식 (VRCA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kirby John J. | Interim CFO |
Nov 25 '25 |
Buy |
4.24 |
3,536 |
15,001 |
8,962 |
| Zawitz David | Chief Operating Officer |
Nov 25 '25 |
Buy |
4.24 |
10,000 |
42,425 |
21,000 |
| Rieger Jayson | CEO and President |
Nov 25 '25 |
Buy |
4.24 |
94,311 |
400,114 |
182,593 |
| Manning Paul B | Director |
Nov 25 '25 |
Buy |
4.24 |
2,750,762 |
11,670,108 |
3,348,372 |
| Manning Paul B | Director |
Nov 25 '25 |
Buy |
4.24 |
1,375,380 |
5,835,050 |
3,958,189 |
2.60%
0.94%
자본화:
|
볼륨(24시간):